A selective and reversible inhibitor of MAO-B (IC50s = 0.48 and 1.5 μM measured in platelets of human subjects ages 19-36 and 60-78, respectively) that is structurally similar to phenyethylamine; evaluated in clinical trials for possible neuroprotectiove actions in the treatment of Parkinson’s disease.